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Abstract
The tumor-selective cytotoxic effect of tumor necro-
sis factor–related apoptosis-inducing ligand (TRAIL)
makes TRAIL an attractive candidate as an anticancer
agent. However, resistance to TRAIL poses a challenge
in anticancer therapy with TRAIL. Therefore, character-
izing the mechanisms of resistance and developing
strategies to overcome the resistance are important
steps toward successful TRAIL-mediated cancer ther-
apy. In this study, we investigated mechanisms of ac-
quired TRAIL resistance in a colon cancer DLD1 cell
line. Compared with the TRAIL-susceptible DLD1 cell
line, TRAIL-resistant DLD1/TRAIL-R cells have a low
level of caspase-8 protein, but not its mRNA. Suppres-
sion of caspase-8 expression by siRNA in parental
DLD1 cells led to TRAIL resistance. Restoration of
caspase-8 protein expression by stable transfection
rendered the DLD1/TRAIL-R cell line fully sensitive
to TRAIL protein, suggesting that the low level of
caspase-8 protein expression might be the culprit in
TRAIL resistance in DLD1/TRAIL-R cells. Sequencing
analysis of the caspase-8 coding region revealed a
missense mutation that is present in both TRAIL-
sensitive and TRAIL-resistant DLD1 cells. Subsequent
study showed that the degradation of caspase-8
protein was accelerated in DLD1/TRAIL-R cells com-
pared to parental DLD1 cells. Thus, accelerated
degradation of caspase-8 protein is one of the mech-
anisms that lead to TRAIL resistance.
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Introduction
Tumor necrosis factor (TNF)–related apoptosis-inducing
ligand (TRAIL), a member of the TNF cytokine family, is
regarded as a potential anticancer agent because of its
strong antitumor activity in a wide range of cancer cell types
and its minimal cytotoxicity to most normal cells and tissues
[1–3]. In addition to its direct apoptosis-inducing effect,
TRAIL also plays an important role in immune surveillance
against tumor initiation, development, and metastasis, indicat-
ing its potential application to cancer immunotherapy [4,5].
However, resistance to TRAIL-mediated apoptosis in can-
cer cells may limit the success of TRAIL-mediated anticancer
therapy. In fact, although many types of cancer cells are
sensitive to TRAIL-induced apoptosis, substantial numbers of
cancer cells are intrinsically resistant to TRAIL, especially
some highly malignant tumors [6,7]. Moreover, we and others
also found that repeated application of TRAIL protein or TRAIL-
expressing adenovectors to TRAIL-susceptible cancer cells
results in the selection and expansion of TRAIL-resistant cells,
leading to acquired resistance [8,9]. In vivo, this acquired
TRAIL resistance may enable cancer cells to escape TRAIL-
mediated immune surveillance and then become metastatic
[4,5]. Thus, characterizing mechanisms of resistance to TRAIL-
mediated apoptosis will provide essential knowledge not only
for TRAIL gene therapy but also for TRAIL immunotherapy.
Theoretically, resistance to TRAIL can occur at different
points in the signaling pathways of TRAIL-induced apoptosis.
In fact, TRAIL resistance in various cancer cells has been
linked to dysfunction of the death receptors DR4 and DR5
due to mutations [10,11], defects in the Fas-associated death
domain (FADD) [12] and caspase-8 [6], overexpression of cel-
lular FADD-like interleukin-1b converting enzyme inhibitory
protein (cFLIP) [13], overexpression of Bcl-2 or Bcl-xL [14],
loss of Bax or Bak function [15,16], high expression of inhibitor
of apoptosis protein (IAP) [17], and reduced release of second
mitochondria-derived activator of caspases (Smac/Diablo)
[18] from the mitochondria to the cytosol. However, for most
cancer cells, the mechanisms of TRAIL resistance are still
largely unknown. Clearly, different molecular events in TRAIL
signaling pathways may be involved in resistance in different
cancer cells.
We previously showed that repeated treatment of TRAIL-
susceptible cancer cells with a TRAIL-expressing adenovector
Address all correspondence to: Dr. Bingliang Fang, Department of Thoracic and Cardiovas-
cular Surgery, Unit 445, The University of Texas M. D. Anderson Cancer Center, 1515
Holcombe Boulevard, Houston, TX 77030. E-mail: bfang@mdanderson.org
Received 22 October 2004; Revised 14 January 2005; Accepted 18 January 2005.
Copyright D 2005 Neoplasia Press, Inc. All rights reserved 1522-8002/05/$25.00
DOI 10.1593/neo.04688
Neoplasia . Vol. 7, No. 6, June 2005, pp. 594 – 602 594
www.neoplasia.com
RESEARCH ARTICLE
led to the selection and expansion of TRAIL-resistant cells
in a human DLD1 colon cancer line [8]. Our studies also
showed that overexpression of Bcl-xL and the lack of activa-
tion of p38 MAP kinase observed in the resistant cells did
not account for the resistant phenotype [8,19]. In the pres-
ent study, we found that a low level of caspase-8 protein
due to protein instability correlates with the resistance ob-
served in DLD1/TRAIL-R cells. Thus, signals involved in
caspase-8 degradation contribute to susceptibility to TRAIL-
mediated apoptosis.
Materials and Methods
Antibodies and Reagents
The rabbit polyclonal antibodies against caspase-9 and
Bid were purchased fromCell Signaling (Beverly, MA). Mouse
monoclonal anti–human PARP and FADD antibodies were
obtained from PharMingen (San Diego, CA). The mouse
anti–human cFLIP (NF6) and caspase-8 (C15) monoclonal
antibodies were purchased from Alexis Biochemicals (San
Diego, CA). The mouse anti–human caspase-8 (5D3) and
caspase-10 (4C1) monoclonal antibodies were obtained from
MBL (Watertown, MA). The rabbit anti–human caspase-3
was provided by Santa Cruz Biotechnology (Santa Cruz,
CA). The mouse monoclonal antibodies against Flag (M2)
and b-actin were obtained from Sigma (St. Louis, MO). Goat
anti–mouse IgG2b and IgG1 were purchased from Southern-
Biotech (Birmingham, AL).
Flag-tagged recombinant TRAIL protein was provided by
Alexis Biochemicals. Recombinant TRAIL protein not tagged
was purchased from R&D Systems (Minneapolis, MN).
PS341 (Bortezomib) was obtained from the pharmacy of
The University of Texas M. D. Anderson Cancer Center
(Houston, TX) and dissolved in phosphate-buffered saline
(PBS). Cycloheximide (CHX) was purchased from Calbio-
chem (La Jolla, CA) and dissolved in ethanol.
Cells and Culture
Human colon cancer cell lines, DLD-1 and DLD1/TRAIL-R,
were grown in RPMI 1640 medium supplemented with 10%
fetal bovine serum, glutamine, and antibiotics. Cells were cul-
tured at 37jC in a humidified incubator containing 5% CO2.
Plasmid or siRNA Transfection
DLD1/TRAIL-R cells stably transfected with the caspase-
8 gene were generated by transfecting DLD1/TRAIL-R cells
with the plasmid vector pcDNA3.1/His C-caspase-8 [20]
using FuGENE-6 (Roche Molecular Biochemicals, Indianap-
olis, IN). Cells were then cultured in RPMI 1640 medium
containing 500 mg/ml G418. G418-resistant single clones
of cells were picked up and caspase-8–overexpressing
clones were identified by Western blot analysis. Caspase-8–
specific siRNA and control siRNA were obtained from the
SMARTpool of Dharmacon, Inc. (Chicago, IL). Transfection
of siRNA was performed with Oligofectamine (Invitrogen,
Carlsbad, CA). The concentrations of siRNA for caspase-8
and control used for each transfection were all 100 nM.
Flow Cytometry Assays
Flow cytometry analysis for apoptosis with PI staining
was performed in the Flow Cytometry Core Laboratory at
our institution (M. D. Anderson Cancer Center) as we
have previously described [8].
Western Blot Analysis
Equal amounts of total cellular protein were separated
by 10% to 12% SDS-PAGE and then transferred to Hybond-
enhanced chemiluminescence membranes (Amersham Bio-
sciences, Piscataway, NJ). The membranes were blocked
with blocking buffer containing 5% low-fat milk and 0.05%
Tween 20 in PBS for 1 hour or overnight at 4jC, washed
three times with PBS-containing 0.05% Tween 20 (PBST),
and then incubated with primary antibodies for at least
1 hour at room temperature or overnight at 4jC. After the
membranes were washed again with PBST, they were in-
cubated with peroxidase-conjugated secondary antibodies
and developed with a chemiluminescent detection kit (Amer-
sham Biosciences). The density of a specific band was det-
ermined by UN-SCAN-IT gel Automated Digitizing System
and normalized with that of b-actin.
DISC Analysis
Cells were spread in 10-cm dishes at a density of 3  106
to 5  106 cells/dish 1 day before treatment. TRAIL-Flag and
M2 Flag Ab were mixed and then put on ice for at least
15 minutes. We then treated the cells with TRAIL-Flag and
M2 Flag Ab mixture or with M2 Flag Ab alone (TRAIL-Flag:
50 ng/ml; M2 Flag Ab: 2 mg/ml) and incubated the cells at
37jC in a cell culture incubator over time. After treatment, we
washed the cells with ice-cold PBS twice and then added
1 ml of lysis buffer including 30 mM Tris–HCl (pH 7.5),
150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM phenyl-
methylsulfonyl fluoride (PMSF), and 1 complete protease
inhibitor cocktail (Roche Molecular Biochemicals) to the dish.
The dish was placed on ice for 30 minutes. The cells were
collected into a microtube, and the tube was centrifuged at
16,000g for 10 minutes at 4jC. We then transferred the
supernatant to a fresh tube. For the unstimulated control, we
added the same concentration of TRAIL-Flag and M2 Flag
Ab mixture after cell lysis. Then 30 ml of Sepharose 6B
(Sigma) saturated with the same lysis buffer was added
to the cell lysate and incubated for 2 to 4 hours at 4jC in
a rotating shaker. The tube was centrifuged at 1000g for
5 minutes at 4jC, and 2 to 3 mg of the supernatant was
transferred to a fresh tube. Then 20 to 40 ml of protein A/G
plus agarose (Santa Cruz Biotechnology) was added to
the tube and incubated for 4 hours or overnight at 4jC in a
rotating shaker. The agarose was washed with lysis buffer
five times by inverting the tube 5 to 10 times for each
washing. After the last washing, the supernatant was re-
moved and discarded, and 60 to 100 ml of 2 loading buffer
was added for Western blot analysis.
Real-Time PCR Assay
Real-time PCR analysis was performed as described
previously [8]. b-Actin was used to normalize loading
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amounts of cDNA. All quantitative PCR experiments were
performed in duplicate or triplicate, and mean values were
calculated for each set of experiments. The primer se-
quences for caspase-8 are 5V-ggacaggaatggaacacacttg-3V
and 5V-ccatgagttggtagattttcaaaatc-3 V, with a FAM-
labeled probe of 5V-atgcaggggctttgaccacgacc-3V. The se-
quences of the primers and probes for CARP1 and CARP2
were described previously [21].
Statistical Analysis
Differences among treatment groups were assessed
with ANOVA using Statistica software. P V .05 was consid-
ered significant.
Results
Lack of TRAIL-Mediated Caspase-8 and Caspase-10
Cleavage in DLD1/TRAIL-R Cells
Depending on the importance of the mitochondria path-
way to TRAIL-induced apoptosis, TRAIL-sensitive cancer
cells can be classified into two types [22]. In type I cells,
apoptosis induced by TRAIL is independent of mitochondrial
activation and cannot be blocked by Bcl-xL and Bcl-2. In type
II cells, TRAIL-mediated apoptosis requires activation of ef-
fector caspases by the mitochondria and can be blocked by
Bcl-xL and Bcl-2 [22]. Because our previous study showed
that Bcl-xL protein overexpression could not protect paren-
tal DLD1 cells from TRAIL-induced apoptosis, the DLD1 cell
line is likely mitochondria-independent type I cancer cells
that require a high level of caspase-8 activity for the sig-
naling of TRAIL-induced apoptosis. Therefore, we focused
on caspase-8, a key molecule involved in DISC. Density
analysis of Western blot bands in untreated cells shown in
Figure 1 revealed that pro–caspase-8 expression at the
protein level was approximately 50% lower in DLD1/
TRAIL-R cells than in DLD1 cells. Moreover, cleaved active
caspase-8 p18 subunit was not detectable after TRAIL
protein treatment in the resistant cell line. The p43 subunit
was detectable but was much weaker than that in parental
DLD1 cells (Figures 1 and 2B). In contrast, TRAIL-mediated
cleavage bands of caspase-8 p43 and p18 subunits were
apparent in the parental DLD1 cell line that is highly suscep-
tible to TRAIL protein treatment. A time course study showed
that TRAIL-mediated cleavage of caspase-8 into its active
form (p18 subunit) was not detectable in the DLD1/TRAIL-R
cells even 72 hours after TRAIL treatment, whereas the
active p18 subunit was easily detectable in DLD1 cells at
2 hours after TRAIL protein treatment. Because caspase-10
was reportedly able to initiate TRAIL-induced apoptosis in
the absence of caspase-8 activation [23], we also tested
caspase-10 cleavage on TRAIL treatment in both cell lines.
The cleavage of caspase-10 was obvious in the parental
DLD1 cells but not detectable in the DLD1/TRAIL-R cells
(Figure 1). Interestingly, density analysis of the caspase-10
bands in untreated cells showed approximately 30% reduc-
tion of caspase-10 in the DLD1/TRAIL-R cells when compared
with the parental DLD1 cells.
Decreased Caspase-8 Recruitment to the DISC in the
DLD1/TRAIL-R Cell Line Treated with TRAIL
DISC formation is a molecular event that occurs at the
early stage of TRAIL-induced apoptosis. On TRAIL binding,
Figure 1. Caspase-8 and caspase-10 expressions and cleavages after treat-
ment with recombinant TRAIL protein. DLD1 and DLD1/TRAIL-R cell lines
were treated with recombinant TRAIL protein at 20 ng/ml over time. Western
blot analysis was performed by using caspase-8 antibody 5D3 and caspase-10
antibody 4C1. Data are shown from one of two experiments with similar results.
Figure 2. DISC analysis. (A) DISC. DLD1 and DLD1/TRAIL-R cell lines were treated with recombinant Flag-TRAIL protein (50 g/ml) and anti-Flag antibody M2
(2 g/ml) mixture for 2 hours (T), M2 (2 g/ml) alone for 2 hours (M2), or without any treatment. For unstimulated control (un), the same concentration of
recombinant Flag-TRAIL protein and anti-Flag antibody M2 mixture was added after cell lysis. (B) Whole lysate Western blot analysis. DLD1 and DLD1/TRAIL-R
cell lines were treated with recombinant TRAIL protein at 20 ng/ml for 2 hours, and then Western blot analysis was then performed. Data are shown from one of two
experiments with similar results.
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activated death receptors recruit and activate the adaptor pro-
tein, FADD. FADD then recruits and activates caspase-8 at
the DISC level [24]. Immunoprecipitation analysis showed
that 2 hours after treatment with Flag-tagged TRAIL protein
(50 ng/ml) and anti-Flag antibody M2 (2 mg/ml), an equal
amount of FADD was recruited to the DISC in both parental
DLD1 and DLD1/TRAIL-R cell lines. However, FADD pro-
tein was not detected in samples treated with anti-Flag
antibody M2 alone or with Flag-tagged TRAIL protein and
anti-Flag antibody M2 after cell lysis (Figure 2A). Because
Western blot analysis of whole cell lysates also showed
an equal amount of FADD protein expression in both cell
lines (Figure 2B), it was apparent that the DISC had no
defects for FADD protein recruitment. Because death
receptors are upstream molecules of FADD in the signaling
of TRAIL-induced apoptosis, the above results also further
support our previous finding that death receptors of TRAIL
do not contribute to TRAIL resistance in the DLD1/TRAIL-R
cell line.
Next, we examined caspase-8 recruitment at the DISC
in both cell lines. Our results showed that pro–caspase-8 and
its p43 subunit could be detected at the DISC in both cell lines
2 hours after treatment with Flag-tagged TRAIL protein and
anti-Flag antibody M2. However, compared with the parental
DLD1 cell line, the amounts of recruitment of both the pro–
caspase-8 and the p43 subunit to theDISC decreased by about
50% in the DLD1/TRAIL-R cell line (Figure 2A). Decreased
caspase-8 recruitment to the DISC after TRAIL protein treat-
ment is consistent with lower expression of caspase-8 protein
in the DLD1/TRAIL-R cell line.
cFLIP is an important antiapoptotic molecule that can be
recruited to the DISC. By binding to FADD or caspase-8,
cFLIP can inhibit caspase-8 activation [13]. However, in the
present study, no difference was found on cFLIP recruitment
to the DISC between the two cell lines (Figure 2A). Also, no
differences were detected in cFLIP expression in whole
lysate samples in both cell lines (Figure 2B). Moreover, the
processing of 55 kDa of cFLIP long form (cFLIPL) into the
cleaved form (43 kDa of cFLIP) by TRAIL also was observed
in both cell lines, indicating that cFLIP was not the primary
cause of TRAIL resistance in the DLD1/TRAIL-R cell line.
This observation is consistent with previous reports that
DISC recruitment of cFLIP and its processing into p43 form
weremediated through the adaptermolecule FADD, andmight
not require active forms of caspase-8 or caspase-10 [25,26].
The Same Mutation of Caspase-8 Occurs in the DLD1
and DLD1/TRAIL-R Cell Lines
Low levels of caspase-8, reduced caspase-8 cleavage,
and decreased caspase-8 recruitment to the DISC after
TRAIL protein treatment in the DLD1/TRAIL-R cell line might
be caused by different mechanisms. First, a functional defect
of caspase-8 may block its full activation by TRAIL. Alterna-
tively, it is possible that caspase-8 function was normal, but
the low level of caspase-8 in the DLD1/TRAIL-R cell line was
sufficient to lead to TRAIL resistance.
To determine the functionality of caspase-8, we se-
quenced the whole codon region of nucleotides of the
caspase-8 gene in both cell lines. No sequence difference
was found between the two. However, compared with the
wild-type caspase-8 gene, the same genetic mutation of the
caspase-8 gene was found in both DLD1 and DLD1/TRAIL-R
cell lines. This missense mutation occurred at nucleotide
695 from the caspase-8 start codon, where a C-to-A change
resulted in substitution of a histidine for proline (Figure 3).
Because this mutation occurred in both cell lines, it is likely
that the mutation does not lead to caspase-8 malfunction.
Downregulation of Caspase-8 by Caspase-8 siRNA in the
DLD1 Cell Line Inhibits TRAIL-Induced Apoptosis
Because no functional abnormality of caspase-8 was
found in both parental and resistant cell lines, we then tested
whether downregulation of caspase-8 expression could re-
duce TRAIL-mediated cell death in the parental DLD1 cell
line. As shown in Figure 4A, caspase-8 was substantially
downregulated in parental DLD1 cells 48 and 72 hours after
transfection with caspase-8 siRNA, but not with a control
siRNA. This downregulation of caspase-8 by siRNA also
rendered a significant decrease of the sensitivity to TRAIL
(Figure 4B). Twenty-four hours after treatment with 20 ng/ml
TRAIL protein, the sub-G1 population decreased from 69.5%
to 73.4% in samples that were not transfected or transfected
with control siRNA to 37.4% to 44.9% in samples that were
transfected with caspase-8 siRNA. This result demonstrates
Figure 3. Schematic representation of sequencing analysis of nucleotides of caspase-8 coding region. RT-PCR of the caspase-8 coding region for both DLD1 and
DLD1/TRAIL-R cell lines was performed with the following caspase-8 PCR primers: 5 V-atggacttcagcagaaatc-3 V and 5 V-gcaccatcaatcagaaggg-3 V. The sequencing of
the PCR products was performed in the Sequencing Laboratory at our institution (M. D. Anderson Cancer Center).
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that the level of caspase-8 expression is critical for TRAIL
sensitivity in the DLD1 cell line. Because the levels of
caspase-10 expression in the DLD1 cell line remained un-
changed after caspase-8 siRNA transfection (data not
shown), it is clear that, in DLD1 cells, the function of
caspase-8 in triggering TRAIL-induced apoptosis could not
be replaced by caspase-10.
Reconstitution of Caspase-8 Restores Cellular Sensitivity
of DLD1/TRAIL-R Cells to TRAIL
To test whether the low level of caspase-8 protein in the
DLD1/TRAIL-R cell line is a key molecular event for TRAIL
resistance, we restored caspase-8 protein expression in the
DLD1/TRAIL-R cell line by plasmid transfection. After the
caspase-8–expressing plasmid transfection into DLD1/
TRAIL-R cells and G418 selection, we obtained a set of
G418-resistant clones. Because the caspase-8 introduced
by plasmid transfection contains a his-tag at the N-terminal,
the mobility of the exogenous caspase-8 protein on PAGE in
Western blot analysis is slower than that of the endogenous
caspase-8 protein. Among the clones tested for exogenous
caspase-8 protein expression, clones 7 and 23 showed
nearly equivalent amounts of exogenous caspase-8 expres-
sion. These were also comparable to the expression level of
endogenous caspase-8 in the parental DLD1 cell line. Clone
4 showed a slight increase in caspase-8 expression. How-
ever, the vector control sample and clones 1 and 2 did not
show any exogenous caspase-8 expression (Figure 5A). We
then tested the TRAIL sensitivity of these selected clones. As
shown in Figure 5B, 24 hours after treatment with 20 ng/ml
TRAIL protein, the percentages of apoptotic cells (sub-G1)
in the vector control sample, clone 1, and clone 2 were
between 4.5% and 7.9%, similar to that of the DLD1/
TRAIL-R cell line after the same treatment (2.9%). Clone 4
displayed a slight increase in sub-G1 population (18.3%). In
comparison, clones 7 and 23 were highly sensitive to TRAIL,
with 42.0% to 52.0% of their cells undergoing apoptosis
after TRAIL protein treatment, an outcome similar to what
is seen in parental DLD1 cells (41.9%). Because TRAIL
sensitivity in these selected clones correlated with cas-
pase-8 protein expression levels and because DLD1 cells,
clone 7, and clone 23 showed comparable caspase-8 pro-
tein expression and apoptosis after TRAIL treatment, resto-
ration of caspase-8 expression is sufficient to resensitize the
DLD1/TRAIL-R cell line to TRAIL. This result also suggests
that the reduced expression of caspase-10 in DLD1/TRAIL-R
cells may not contribute to TRAIL resistance.
To further demonstrate that the levels of caspase-8 ex-
pression are important to TRAIL sensitivity, we then tested
whether the downregulation of the exogenous caspase-8
expression in clone 7 could reduce its TRAIL sensitivity. At
48 hours after transfection with caspase-8 siRNA, expres-
sion of caspase-8 was reduced by about 50% in clone 7
(Figure 6A), which correlated with a reduced apoptosis
induction by TRAIL (Figure 6B). Twenty-four hours after
treatment with 20 ng/ml TRAIL protein, the sub-G1 popula-
tion decreased from 53.9% to 55.7% in samples that were
not transfected or transfected with control siRNA, to 31.6%
Figure 4. Effects of caspase-8 siRNA on TRAIL-induced apoptosis in DLD1
cell line. (A) Downregulation of caspase-8 by caspase-8 siRNA. DLD1 cells
were transfected with control siRNA or caspase-8 siRNA at 100 nM for 48 or
72 hours, and then caspase-8 expression was analyzed by Western blot
analysis. (B) TRAIL-induced apoptosis in siRNA-transfected DLD1 cells. After
siRNA transfection, cells were treated with TRAIL protein at 20 ng/ml for
24 hours, and then the percentage of apoptotic (sub-G1) cells was
determined by FACS. Values are mean ± SD of triplicate assays. The
percentage of sub-G1 cells after TRAIL treatment is significantly lower in
caspase-8 siRNA-transfected DLD1 cells than that of nontransfected or
control siRNA-transfected DLD1 cells (P < .01).
Figure 5. Effects of restoration of caspase-8 protein expression on TRAIL-
induced apoptosis in DLD1/TRAIL-R cell line. (A) Western blot analysis of
pcDNA3.1/His C-caspase-8 stably transfected DLD1/TRAIL-R cell clones.
Lane 1, DLD1 cells; lane 2, DLD1/TRAIL-R cells; lane 3, DLD1/TRAIL-R cells
transfected with the empty vector; lanes 4 to 8, DLD1/TRAIL-R cells
transfected with pcDNA3.1/His C-caspase-8: clone 1 (lane 4), clone 2 (lane 5),
clone 4 (lane 6), clone 7 (lane 7), and clone 23 (lane 8). (B) Apoptosis in-
duced by TRAIL in caspase-8 stably transfected DLD1/TRAIL-R cell clones.
Cells were treated with recombinant TRAIL protein at 20 ng/ml for 24 hours.
The percentage of apoptotic (sub-G1) cells was determined by FACS. Values
are mean ± SD for duplicate assays of two experiments. The digital numbers
under the x-axis indicate cell lines: (1) DLD1 cells; (2) DLD1/TRAIL-R cells;
(3) DLD1/TRAIL-R cells transfected with the empty vector; (4–8) DLD1/
TRAIL-R cells transfected with pcDNA3.1/His C-caspase-8: clone 1 (4), clone
2 (5), clone 4 (6), clone 7 (7), and clone 23 (8).
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in samples that were transfected with caspase-8 siRNA. This
result further supported the importance of the levels of
caspase-8 in TRAIL-mediated apoptosis.
Western blot analysis showed that marked levels of
caspase-8–cleaved subunits p43 and p18 were observed
in the DLD1 cell line and clone 7 treated with TRAIL protein,
but not in the DLD1/TRAIL-R cell line given the same
treatment (Figure 6C). Of note, the mobility of the major
subunit p43 in clone 7 treated with TRAIL protein was slower
than that in the DLD1 cell line given the same treatment
because this subunit p43 comes from the N-terminal of
caspase-8 and is his-tagged in exogenous caspase-8. In ad-
dition to the exogenous p43 subunit, we also can see a weak
endogenous p43 subunit band in clone 7 treated with the
TRAIL protein, which has the same mobility as the p43 sub-
unit in the DLD1 cell line, suggesting that both exogenous
and endogenous caspase-8 may work together for the res-
toration of cellular sensitivity of the DLD1/TRAIL-R cells to
TRAIL. Subunit p18 of caspase-8 remained the same size in
both the DLD1 cell line and clone 7 (Figure 6C). Moreover, in
both the parental DLD1 cell line and clone 7, treatment with
TRAIL protein resulted in a reduction in Bid protein and an
increase in cleavage of caspase-3, caspase-9, and PARP
(Figure 6D), demonstrating that when caspase-8 is acti-
vated, apoptosis ensues in those cells.
Accelerated Degradation of Caspase-8 Protein in the
DLD1/TRAIL-R Cell Line
To understand the mechanisms of low caspase-8 expres-
sion in the DLD1/TRAIL-R cell line, we tested caspase-8
mRNA levels by real-time PCR. Interestingly, the DLD1 and
DLD1/TRAIL-R cell lines had equivalent caspase-8 mRNA
(Figure 7A), indicating that the low level of caspase-8 protein
in the DLD1/TRAIL-R cell line was not caused by reduced
transcription of caspase-8 mRNA. Compared with the DLD1
and DLD1/TRAIL-R cell lines, clone 7 showed an approxi-
mate 150% increase in caspase-8 mRNA expression due to
exogenous caspase-8 expression from the transfection of the
caspase-8–expressing plasmid (Figure 7A).
We then tested caspase-8 protein degradation. To do so,
we blocked de novo protein synthesis with the protein
synthesis inhibitor, CHX. Cells were then harvested over
time, and pro–caspase-8 was determined by Western blot
analysis. The DLD1/TRAIL-R cell line exhibited a faster
caspase-8 protein degradation rate than did the parental
DLD1 cell line. The half-life of caspase-8 protein in the DLD1/
Figure 6. Effects of exogenous caspase-8 expression in clone 7. (A) Downregulation of caspase-8 by caspase-8 siRNA. Clone 7 cells were transfected with control
siRNA or caspase-8 siRNA at 100 nM for 48 hours, and then caspase-8 expression was analyzed by Western blot analysis. (B) TRAIL-induced apoptosis in siRNA-
transfected clone 7 cells. After siRNA transfection, cells were treated with TRAIL protein at 20 ng/ml for 24 hours, and then the percentage of apoptotic (sub-G1)
cells was determined by FACS. Values are mean ± SD for a triplicate assay. The percentage of sub-G1 cells after TRAIL treatment is significantly lower in caspase-
8 siRNA-transfected clone 7 cells than that of nontransfected or control siRNA-transfected clone 7 cells (P < .01). (C) Exogenous caspase-8 cleavage after TRAIL
treatment. Cells were treated with recombinant TRAIL protein at 20 ng/ml for 2 hours, and then Western blot analysis was performed on caspase-8 expression and
cleavage. (D) Cleavage of caspase-8 downstream molecules after TRAIL protein treatment. Cells were treated with recombinant TRAIL protein at 20 ng/ml for
2 hours, and then Western blot analysis was performed on expression and cleavage of caspase-3, caspase-9, Bid, and PARP.
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TRAIL-R cell line was about 3.5 hours; however, it was
longer than 9 hours in the parental DLD1 cell line (Figure 7,
B and C), and this may explain the low level of caspase-
8 protein expression in the DLD1/TRAIL-R cell line.
More recently, it was reported that caspase-8 is degraded
by the CARP1- and CARP2-mediated ubiquitin/proteasome
pathway [21]. Therefore, we investigated CARP1 and
CARP2 gene expression by the real-time PCR method. Both
CARP1 and CARP2 genes encode RING domain-containing
proteins and have E3 ubiquitin ligase activity. When overex-
pressed, CARP1 and CARP2 cause rapid degradation of
exogenous caspase-8 and caspase-10, but not other cas-
pases such as caspase-9 [21]. Compared with the DLD1
cell line, the DLD1/TRAIL-R cell line showed a 30% to
50% increase in mRNA levels in both CARP1 and CARP2
(Figure 7D), suggesting that these CARPs may be involved
in the fast caspase-8 protein degradation in DLD1/TRAIL-R
cells. Nevertheless, treatment of both parental DLD1 and
DLD1/TRAIL-R cell lines with 1 mM PS341, a specific pro-
teasome inhibitor, for 6 hours did not change the caspase-
8 basal levels in both cell lines (Figure 7E ), although this
treatment effectively reversed TRAIL resistance in DLD1/
TRAIL-R cells (data not shown). Pretreatment with PS341
also did not alter the rates of caspase-8 degradation in
both cell lines (Figure 7E ). Similar results were obtained
with other proteasome inhibitors, MG 132 and ALLN (data
not shown) (see Discussion section).
Discussion
In the present study, we found that a low level of caspase-8
protein is the key molecular event that causes TRAIL re-
sistance in colon cancer DLD1 cells. This low level of
caspase-8 expression is likely caused by increased deg-
radation, rather than reduced transcription. Because the
coding sequence for caspase-8 is the same for both resis-
tant and parental susceptible cells, the instability probably
is not caused by caspase-8 itself. It is possible that the
machinery for caspase-8 degradation is to blame for the
low caspase-8 expression.
Caspase-8 activation is the initial step in the TRAIL-mediated
caspase activation cascade. Lack of caspase-8 expression has
Figure 7. Rapid caspase-8 protein degradation in DLD1/TRAIL-R cell line. (A) Caspase-8 expression at mRNA level. Real-time PCR was performed for mRNA
expression of caspase-8 in DLD1, DLD1/TRAIL, and clone 7 cells. Values are mean ± SD for two duplicate assays. (B) Caspase-8 protein expression after
treatment with CHX. DLD1 and DLD1/TRAIL-R cell lines were treated with 20 g/ml CHX for different times, and then caspase-8 protein expression was
determined by Western blot analysis. Data are shown from one of three experiments with similar results. (C) Relative caspase-8 abundance. Photo density of
bands in (B) was determined by UN-SCAN-IT gel Automated Digitizing System. Relative caspase-8 abundance was normalized to -actin. (D) mRNA expression of
CARP1 and CARP2 genes. Real-time PCR was performed for mRNA expression of CARP1 and CARP2 genes in DLD1 and DLD1/TRAIL cells. Values are mean ±
SD for a triplicate assay. (E) Effects of proteasome inhibitor, PS341, on caspase-8 degradation. DLD1 and DLD1/TRAIL-R cell lines were pretreated with 1 M
PS341 or PBS for 6 hours, and then treated with 20 g/ml CHX for another 6 or 18 hours. Caspase-8 expression was analyzed by Western blot analysis.
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been reported to cause TRAIL resistance [27]. It is interest-
ing that low levels of caspase-8 expression also can lead to
dramatic resistance to TRAIL. This phenomenon may not be
limited to DLD1 cells. Lovo/TRAIL-R, another colon cancer
cell line derived from TRAIL-susceptible Lovo cells through
repeated treatment of TRAIL protein, also has greatly re-
duced levels of caspase-8 protein when compared with
parental cells (data not shown). However, despite apparent
downregulation of caspase-8 protein in the DLD1/TRAIL-R
cell line, we still can detect caspase-8 protein expression
and its DISC recruitment after TRAIL treatment. Interest-
ingly, in the TRAIL-resistant cells, cleavage of caspase-8 is
not fully executed, as evidenced by the lack of an 18-kDa
band in the resistant cell line after the TRAIL treatment. DISC
recruitment for FADD and cFLIP after the TRAIL treatment
remained the same for both susceptible and resistant
cells. It remains unknown whether the ratio of cFLIP and
caspase-8 recruited to DISC played any role in the full
cleavage of caspase-8.
We also found that caspase-10, with a similar structure as
caspase-8, was also downregulated at protein level in the
TRAIL-resistant cells. Whether this downregulation is also
caused by accelerated protein degradation is not clear. Sim-
ilar to caspase-8, TRAIL-mediated activation of caspase-10
was detected in parental DLD1 cells but not in DLD1/TRAIL-
R cells. However, studies with caspase-8–specific siRNA
and caspase-8 stably transfectant cells suggested that the
level of caspase-8 is more critical for TRAIL-mediated apo-
ptosis in DLD1 cells.
Deficiency or low levels of caspase-8 expression have
been reported in a number of cancer cell lines [6,27,28] and
in primary tumor tissues of neuroblastomas, childhood me-
dulloblastomas, and small cell lung carcinomas [28–30]. It is
also reported that loss of caspase-8 activation is a possible
mechanism for the resistance of human laryngeal cancer
cells to cisplatin-induced apoptosis [31]. However, those low
levels of caspase-8 expression were usually explained by
low transcription caused by either DNA methylation in its
promoter region, or by caspase-8 gene deletion [6,27,28].
In our study, we did not find significant changes in the ex-
pression level of caspase-8 mRNA between the parental
DLD1 and the DLD1/TRAIL-R cell lines. However, we found
a faster degradation of caspase-8 protein in the DLD1/
TRAIL-R cell line, suggesting that protein degradation is
an important step in the regulation of protein levels. The
ubiquitin–proteasome pathway regulates a broad range of
cellular functions, including apoptosis, through degradation
of various vital regulatory cellular proteins [32]. For TRAIL-
mediated apoptosis signaling, proteasome inhibitors can
decrease the cFLIP protein level, promote Bax translocation
to mitochondria, and eliminate the binding of the IAPs to
caspase-3, caspase-7, and caspase-9 [33]. Nevertheless,
even though treatment with proteasome inhibitors such as
ALLN [34] or PS-341 can effectively reverse TRAIL resis-
tance in DLD1/TRAIL-R cells, treatment with proteasome
inhibitors alone did not change the caspase-8 basal levels in
both cell lines tested. A possible explanation for this obser-
vation is that an alternative protein degradation pathway
may be involved in caspase-8 degradation. It is also possible
that those proteasome inhibitors alone are not sufficient to
block protein degradation by proteasome. For example, it is
reported that simultaneous inhibitions of proteasome activity
and protein phosphorylation are required to block the deg-
radation of Snail, a zinc-finger transcription factor, whereas
proteasome inhibitor or protein kinase inhibitor alone did
not block the degradation of this protein [35].
CARPs are RING domain-containing proteins that have
E3 ubiquitin ligase activity and were reported to promote
proteasomal degradation of death effective domain (DED)–
containing caspases, such as caspase-8 and caspase-10
[21]. Compared with the DLD1 cell line, the DLD1/TRAIL-R
cell line showed a 30% to 50% increase in mRNA levels in
both CARP1 and CARP2 (Figure 7D). This result indicates
that CARPs may be involved in the fast caspase-8 protein
degradation in DLD1/TRAIL-R cells. However, it is still un-
clear whether CARPs are only E3 ligase proteins involved
in caspase-8 ubiquination and degradation. For example,
although the overexpression of CARP genes causes caspase-
8 and caspase-10 degradation, siRNA-mediated down-
regulation of CARPs cannot effectively change the basal
levels of caspase-8 or caspase-10 [21]. This suggests that
molecules other than CARPs may also be implicated in
caspase-8 degradation. Defining genes or proteins involved
in caspase-8 degradation may help us to elucidate mecha-
nisms behind this rapid caspase-8 protein degradation in
the DLD1/TRAIL-R cell line.
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